3D Atopic Dermatitis Model

Disease specific in vitro models for your research​

Skimune® AD
Our advanced Skimune® model stimulated to demonstrate an AD phenotype through addition of inflammatory cytokines and autologous immune cells. ​

Skimune® Epi AD
Based on our Skimune® Epi platform, Skimune® Epi AD exhibits key phenotypical markers of AD in a 96 well plate high throughput format, perfect for larger scale screening requirements. ​

​Custom disease model optimisation, contact us for more information
Get in touch

At a glance

Skimune® AD decreased Filaggrin and increased TSLP expression, typical in Atopic Dermatitis. ​
Addition of steroids are able to reverse this response.​


Testing efficacy of novel drug compounds.​
Mechanistic assessment of immune cell responses to both AD onset and therapies. ​

Skimune® AD​

Benefits of Skimune® AD are:

Real human tissues represent the complexity of in vivo biology
Induced through validated cytokine cocktails and autologous PBMCs to mimic typical Atopic dermatitis responses
Does not rely on patient derived samples
Reduces variability caused by pre-existing treatment regimes
Validated for mechanistic assessment of steroid formulations and monoclonal antibodies
Get in touch
Skimune® AD is a human explant model which is induced to express an Atopic Dermatitis phenotype through co-culture with autologous immune cells and an inflammatory cytokine cocktail.​

Markers for AD phenotypes such as Filaggrin and Thymic Stromal Lyphoprotein (TSLP) are lowered and raised respectively in Skimune® AD similarly to that observed in clinical patient samples (Figure 1). These biomarkers can be detected by immunohistochemistry and quantified in supernatants using ELISA to demonstrate significant differences between stimulated tissues and unstimulated controls (Figure 2). Application of standard AD therapeutics such as hydrocortisone was able to reverse the AD induced phenotype (Figure 1). Skimune® AD is a powerful tool for AD research.​
Figure 1 - H&E and immunostaining for TSLP in control, AD induced, 1% Hydrocortisone treated, and 0.05% Clobetasol Propionate treated conditions. TSLP staining is dramatically reduced in treated samples. ​
Figure 2 - ELISA analysis of supernatant Filaggrin and TSLP shows disease specific changes in AD induced models.​

Skimune® Epi AD​

Benefits of Skimune® Epi AD are:

Cytokine induced epidermal model allows for high throughput assessment of disease modifying treatments
Get in touch
Alcyomics is also in the process of developing an epidermal Atopic Dermatitis model for high throughput screening needs (Figure 1).

Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models. ​
Figure 1 - Skimmune® Epi AD
Figure 2 - TMSP and Filaggrin immunofluorescence staining increased and decreased in AD induction.

Other Tissue Engineering 3D Assay Platform Solutions

Cell bioprinting

Read more

3D Atopic Dermatitis Model

Read more

3D Tissue Modelling

Read more

Get in touch

How can we assist?